

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill
No. ER 535435704 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450, on the date shown below.

Dated: January 20, 2004

Signature: Leeyun

PATENT
Docket No. 559082001800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Anthony E. BOLTON, et al.

Serial No.: 09/866,488

Filing Date: May 25, 2001

For: APOPTOTIC ENTITIES FOR USE IN
TREATMENT OF T-CELL-MEDIATED AND
INFLAMMATORY DISORDERS

Examiner: M. Yu

Group Art Unit: 1642

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the
above-identified application the documents listed on the attached Form PTO-1449. Copies of the
documents are also submitted herewith. The Examiner is requested to make these documents of
record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.

01/28/2004 LEONDIH1 00000116 09866488

02 FC:1806

180.00 DP

- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
- ☒ A fee is required. A check in the amount of \$180.00 is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.



In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-2859** referencing 559082001800. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 20, 2004

Respectfully submitted,

By: 
Gerald F. Swiss
Registration No. 30,113

Swiss Law Group
Building 3, Palo Alto Square
3000 El Camino Real, Suite 100
Palo Alto, California 94306
Telephone: (650) 856-3700
Facsimile: (650) 856-3710

PTO-Form 1449

ATTY DOCKET NO.

55908-20018.00

APPLICATION NO

09/866,488

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Anthony E. BOLTON, et al.

FILING DATE

May 25, 2001

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

1.	ADORINI, L. "Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases," <i>CMLS Cell. Mol. Life. Sci.</i> 55: 1610-1625 (1999).
2.	DE FOUGEROLLES, A.R., et al. "Regulation of inflammation by collagen-binding integrins $\alpha 4 \beta 1$ and $\alpha 2 \beta 1$ in models of hypersensitivity and arthritis," <i>The Journal of Clinical Investigation</i> 106(6): 721-729 (2000).
3.	PARK, S., et al. "Shift Toward T Helper 1 Cytokines by Type II Collagen-Reactive T Cells in Patients with Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> 44(3): 569-569 (2001).
4.	PEEVA, E., et al. "Rheumatoid Arthritis Exacerbation Caused by Exogenous Interleukin 12," <i>Arthritis & Rheumatism</i> 42(2): 461-463 (2000).
5.	PERLMAN, H., et al. "IL-6 Matrix Metalloproteinase-1 Are Regulated by the Cyclin-Dependent Kinase Inhibitor p21 in Synovial Fibroblasts," <i>The Journal of Immunology</i> 170: 838-845 (2003).
6.	SPADARO, A., et al. "Il ruolo dell'Interleuchina-12 nelle malattie reumatiche a patogenesi immunitaria," <i>Reumatismo</i> 54(2): 113-121 (2002). ABSTRACT IN ENGLISH
7.	TAYLOR, P.C. "Anti-TNF α Therapy for Rheumatoid Arthritis: an Update," <i>Internal Medicine</i> 42(1): 15-20 (2003).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.